FDA Grants Orphan Drug Status to SOM Biotech’s Chorea Therapy

FDA Grants Orphan Drug Status to SOM Biotech’s Chorea Therapy

309585

FDA Grants Orphan Drug Status to SOM Biotech’s Chorea Therapy

The U.S. Food and Drug Administration (FDA) has granted an orphan drug designation to SOM3355, an investigational treatment for chorea, or involuntary jerky movements, associated with Huntington’s disease, its developer SOM Biotech has announced. Orphan drug status helps to encourage the development of therapies for rare and serious diseases, through benefits for developers, such as seven years of market exclusivity and exemption from FDA application fees. Chorea is the most common involuntary movement symptom in…

You must be logged in to read/download the full post.